Loading organizations...
Clinipace is a technology company.
Clinipace, now operating as Caidya, functions as a global, multi-therapeutic Contract Research Organization (CRO). The firm delivers a comprehensive range of clinical services, extending from early-phase development and strategic pre-IND planning through full clinical trials to post-marketing surveillance. Caidya integrates proprietary clinical technology and data-driven methodologies to optimize trial transparency and decision-making for clients across diverse therapeutic areas including oncology, rare diseases, and cardiology.
The company was founded in 2003 as Clinipace by Jeff Williams and Chris Porter. Their initial insight focused on establishing a technology-enabled contract research organization dedicated to streamlining and enhancing the efficiency of the clinical trial process. Williams notably served as the long-standing CEO, guiding the company's expansion within the specialized clinical research sector for over a decade.
Caidya primarily supports biopharmaceutical innovators across the globe, facilitating the advancement of new therapies. Its overarching mission is to liberate clinical research by prioritizing client objectives, promoting transparent communication, and ensuring diligent project ownership. The company strives to enhance the accessibility of clinical development and ultimately contribute to improved healthcare outcomes for patients worldwide, continuously adapting to the evolving landscape of drug development.
Clinipace has raised $154.0M across 8 funding rounds.
Clinipace has raised $154.0M in total across 8 funding rounds.
Clinipace (now operating under the Caidya group) is a global clinical research organization (CRO) that provides technology-enabled, full-service clinical development and trial execution for biopharmaceutical and medical device sponsors.[4][3]
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech and Biopharma Landscape
Quick Take & Future Outlook
Quick take: Clinipace’s transition into the Caidya group reflects a strategic bet that combining digital-first tools with expanded global operational capacity will win more specialty and mid‑market clinical development work—if the company can show consistent, measurable improvements in trial speed, cost, and data transparency versus legacy CRO alternatives.[4][1][3]
Clinipace has raised $154.0M in total across 8 funding rounds.
Clinipace's investors include Springhill Fund, Rock Springs Capital, Superstring Capital, Hatteras Venture Partners, Lytical Ventures, Osage University Partners, Bill Gates, Jesse Watson, Crestline Investors, Harbert Venture Partners, Mario Family Funds, Morgan Stanley.
Clinipace has raised $154.0M across 8 funding rounds. Most recently, it raised $50.0M Series C in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 7, 2021 | $50.0M Series C | Springhill Fund | Rock Springs Capital, Superstring Capital |
| Mar 14, 2019 | $4.0M Other Equity | ||
| Mar 1, 2018 | $20.0M Venture Round | Hatteras Venture Partners, Lytical Ventures, Osage University Partners, Bill Gates | |
| Nov 19, 2017 | $3.0M Other Equity | ||
| Jan 15, 2015 | $50.0M Other Equity | Jesse Watson | Crestline Investors, Harbert Venture Partners, Hatteras Venture Partners, Mario Family Funds, Morgan Stanley |
| Oct 1, 2012 | $9.0M Series C | Lytical Ventures, Osage University Partners, Bill Gates | |
| Sep 1, 2011 | $15.0M Series C | Melissa Daniels | Hatteras Venture Partners, Lytical Ventures, Osage University Partners, Bill Gates, Brook Private Equity Advisors |
| Jan 1, 2008 | $3.0M Series B | Hatteras Venture Partners, Osage University Partners |